Abattis Bioceuticals Corp  

(Public, CNSX:ATT)   Watch this stock  
Find more results for cnsx:flu
0.540
+0.010 (1.89%)
Jul 31 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range 0.52 - 0.55
52 week 0.02 - 3.10
Open 0.53
Vol. 143,782.00
Mkt cap     -
P/E     -
Div/yield     -
EPS     -
Shares 57.87M
Beta     -
Inst. own     -

Address

SUITE 1000 - 355 BURRARD STREET
VANCOUVER, BC V6C 2G8
Canada
+1-604-5386650 (Phone)
+1-604-8881519 (Fax)

Website links

Description

Abattis Bioceuticals Corp, formerly Abattis Biologix Corporation, is a Canada-based company. On April 16, 2009, the Company entered into an agreement with PRB Pharmaceuticals, Inc. (PRB) and Pacific Bio-Pharmaceuticals, Inc. (Pacific Bio) for the purchase of their interest in patents and intellectual property related to anti viral products, which are designed to prevent avian influenza in humans and poultry. Effective April 7, 2014, Abattis Bioceuticals Corp acquired 51% interest in Phytalytics LLC. In May 2014, the Company, through its subsidiary Abattis Bioceuticals International Inc, raised its interest to 60% from 26%, by acquiring a 34% stake in Instant Payment Systems LLC.

Officers and directors

Mike Withrow President, Chief Executive Officer, Director
Rene David Chief Financial Officer, Chief Operating Officer
Terence Fealey Ph.D. Independent Director
Age: 66
Douglas J. Sorocco Independent Director